Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors
Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors
复制标题
DOI：
10.3892/ol.2019.9959
复制
发表时间：
2019-03-01
期刊：
影响因子：
2.9
通讯作者：
Kondo, Tadashi
中科院分区：
文献类型：
--
作者：
Jia, Xiaotian;Chen, Chao;Kondo, Tadashi
恶性周围神经鞘瘤（MPNST）是侵袭性软组织肉瘤。据报道，MPNST的预后在以前的研究中存在差异。然而，已经报道了许多与MPNST相关的预后生物标志物。本研究采用蛋白质组学方法，探讨不同类型MPSNTs患者的蛋白质表达差异。方法：收集2002年1月至2011年12月在复旦大学附属华山医院手外科手术治疗的30例原发性四肢MPNST患者的临床资料。共有16名患者在5年内死于疾病，而14名患者无病超过5年。来自2年内死亡的9名患者的样品被分配到D组，而来自诊断后连续无病>5年的8名患者的样品被分配到L组用于蛋白质组学研究。采用无标记定量蛋白质组学和质谱技术筛选不同疾病MPSNTs患者的差异蛋白。核心蛋白聚糖作为一个值得注意的差异蛋白被过滤。D组核心蛋白聚糖的表达水平明显低于L组（D/L=0.0948; P=0.0004）。30例MPNST患者的原发肢体标本经免疫组化染色证实。decorin阳性表达者5年生存率为78.57%，decorin阴性表达者5年生存率为18.75%（P=0.0014）。总的来说，高水平的核心蛋白聚糖表明MPNST患者的预后更好。随着进一步研究，核心蛋白聚糖可能是MPNST的可靠预后生物标志物。
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas. The prognosis of MPNSTs has been reported to differ among previous studies. However, there have been a number of reported prognostic biomarkers associated with MPNSTs. In the present study, a proteomics study was performed to discover the differential protein expression in patients with MPSNTs with different prognoses. The clinical data of 30 primary extremities of patients with MPNSTs, who underwent surgery at the Department of Hand Surgery, Huashan Hospital, Fudan University between January 2002 and December 2011, were acquired. A total of 16 patients succumbed to their diseases within 5 years, whereas 14 patients were disease-free for >5 years. Samples from the 9 patients who succumbed within 2 years were assigned to Group D, while samples from the 8 patients who were continuously disease-free for >5 years following diagnosis were assigned to Group L for the proteomics study. Label-free quantitative proteomics and mass spectrometry were performed to filtrate differential protein in patients with MPSNTs with different prognoses. Decorin was filtrated as a differential protein of note. The expression level of decorin was significantly lower in Group D compared with that in Group L (D/L=0.0948; P=0.0004). The result was verified by immunohistochemical staining in the 30 primary extremities of patients with MPNSTs. The 5-year survival rate of patients with positive expression of decorin was 78.57%, while the 5-year survival rate of patients negative for decorin expression was 18.75% (P=0.0014). Overall, a high level of decorin indicted a better prognosis in patients with MPNSTs. With further investigation, decorin may be a reliable prognostic biomarker for MPNSTs.